LBRX
LB PHARMACEUTICALS INCBS score 48.0MEDIUMPHASE3 · mkt cap $753.9M · rev ttm $0
drug hypothesis
LB-102 modulates Unknown - not disclosed in provided filing data to treat Schizophrenia.
moa:Unknown - not disclosed in provided filing data; appears to be an antipsychotic for schizophrenia based on trial indication
score breakdown
trial design55
base rate disconnect15
language red flags100
composite48.0
valuation analysis
market cap$753.9M
revenue ttm$0
phasePHASE3
historical base rate30%
disconnect ratio0.5x
lead trialNCT07363577
meta
cik0001691082
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 1, non-randomized, double-blind trial in 64 healthy adults to evaluate safety and tolerability of single and multiple doses; primary focus on PK parameters including Tmax, Cmax, and AUC
primary endpoint:Percentage of participants who experience at least one treatment-emergent adverse event (TEAE) (Day 8 Part A or Day 15 Part B)
claimed differentiation
Not disclosed in provided filing data
language red flags
- Very limited public information provided - target, mechanism, and preclinical data not disclosed
- Phase 1 in healthy volunteers rather than schizophrenia patients - efficacy in target population untested
- Small enrollment (n=64) provides limited safety signal detection
- No claimed differentiation or competitive positioning provided in available data
- Indication (schizophrenia) is a historically challenging therapeutic area with high failure rates